European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia von Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R.

Volltext

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors von Traer, E, MacKenzie, R, Snead, J, Agarwal, A, Eiring, A M, O'Hare, T, Druker, B J, Deininger, M W

Volltext

Novel approaches to treating advanced systemic mastocytosis von Gilreath, J A, Tchertanov, L, Deininger, M W

Volltext

Age-related mutations and chronic myelomonocytic leukemia von Mason, C C, Khorashad, J S, Tantravahi, S K, Kelley, T W, Zabriskie, M S, Yan, D, Pomicter, A D, Reynolds, K R, Eiring, A M, Kronenberg, Z, Sherman, R L, Tyner, J W, Dalley, B K, Dao, K-H, Yandell, M, Druker, B J, Gotlib, J, O'Hare, T, Deininger, M W

Volltext

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias von Cortes, J.E, Kim, D.-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F.E, Apperley, J.F, Khoury, H.J, Talpaz, M, DiPersio, J, DeAngelo, D.J, Abruzzese, E, Rea, D, Baccarani, M, Müller, M.C, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, V.M, Clackson, T, Turner, C.D, Haluska, F.G, Guilhot, F, Deininger, M.W, Hochhaus, A, Hughes, T, Goldman, J.M, Shah, N.P, Kantarjian, H

Volltext

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib von SHERBENOU, D. W, WONG, M. J, DEININGER, M. W, HUMAYUN, A, MCGREEVEY, L. S, HARRELL, P, YANG, R, MAURO, M, HEINRICH, M. C, PRESS, R. D, DRUKER, B. J

Volltext

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib von Qiang, W, Antelope, O, Zabriskie, M S, Pomicter, A D, Vellore, N A, Szankasi, P, Rea, D, Cayuela, J M, Kelley, T W, Deininger, M W, O’Hare, T

Volltext

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia von Wagle, M, Eiring, A M, Wongchenko, M, Lu, S, Guan, Y, Wang, Y, Lackner, M, Amler, L, Hampton, G, Deininger, M W, O'Hare, T, Yan, Y

Volltext

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia von Eiring, A M, Page, B D G, Kraft, I L, Mason, C C, Vellore, N A, Resetca, D, Zabriskie, M S, Zhang, T Y, Khorashad, J S, Engar, A J, Reynolds, K R, Anderson, D J, Senina, A, Pomicter, A D, Arpin, C C, Ahmad, S, Heaton, W L, Tantravahi, S K, Todic, A, Colaguori, R, Moriggl, R, Wilson, D J, Baron, R, O'Hare, T, Gunning, P T, Deininger, M W

Volltext

Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors von Nardi, V, Raz, T, Cao, X, Wu, C J, Stone, R M, Cortes, J, Deininger, M W N, Church, G, Zhu, J, Daley, G Q

Volltext

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C von Müller, M C, Gattermann, N, Lahaye, T, Deininger, M W N, Berndt, A, Fruehauf, S, Neubauer, A, Fischer, T, Hossfeld, D K, Schneller, F, Krause, S W, Nerl, C, Sayer, H G, Ottmann, O G, Waller, C, Aulitzky, W, Coutre, P le, Freund, M, Merx, K, Paschka, P, König, H, Kreil, S, Berger, U, Gschaidmeier, H, Hehlmann, R, Hochhaus, A

Volltext

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia von Sherbenou, D W, Hantschel, O, Turaga, L, Kaupe, I, Willis, S, Bumm, T, Press, R D, Superti-Furga, G, Druker, B J, Deininger, M W

Volltext

Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo von Bright, S A, McElligott, A M, O'Connell, J W, O'Connor, L, Carroll, P, Campiani, G, Deininger, M W, Conneally, E, Lawler, M, Williams, D C, Zisterer, D M

Volltext

The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis von Demehri, S, O'Hare, T, Eide, C A, Smith, C A, Tyner, J W, Druker, B J, Deininger, M W N

Volltext

Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1 von Zabriskie, M S, Vellore, N A, Gantz, K C, Deininger, M W, O'Hare, T

Volltext

Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells von CHUAH, C, BARNES, D. J, KWOK, M, CORBIN, A, DEININGER, M. W. N, DRUKER, B. J, MELO, J. V

Volltext

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography von DEININGER, M. W. N, MCGREEVEY, L, WILLIS, S, BAINBRIDGE, T. M, DRUKER, B. J, HEINRICH, M. C

Volltext

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia von Agarwal, A, Eide, C A, Harlow, A, Corbin, A S, Mauro, M J, Druker, B J, Corless, C L, Heinrich, M C, Deininger, M W

Volltext

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymp... von Tharkar-Promod, S, Johnson, D P, Bennett, S E, Dennis, E M, Banowsky, B G, Jones, S S, Shearstone, J R, Quayle, S N, Min, C, Jarpe, M, Mosbruger, T, Pomicter, A D, Miles, R R, Chen, W Y, Bhalla, K N, Zweidler-McKay, P A, Shrieve, D C, Deininger, M W, Chandrasekharan, M B, Bhaskara, S

Volltext

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia von Eiring, A M, Khorashad, J S, Anderson, D J, Yu, F, Redwine, H M, Mason, C C, Reynolds, K R, Clair, P M, Gantz, K C, Zhang, T Y, Pomicter, A D, Kraft, I L, Bowler, A D, Johnson, K, Partlin, M Mac, O'Hare, T, Deininger, M W

Volltext